Navigation Links
Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Date:6/26/2012

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

The study randomized 74 patients, ages 16 to 70, to receive either SIR/TAC or MTX/TAC. Patients were stratified by donor relation (siblings or matched, unrelated individuals) and age.

Their study was published in a recent issue of Haematologica, the journal of the European Hematology Association.

"Graft vs. host disease poses major health problems for patients who have received hematopoietic cell transplants and threatens the long-term success of their transplant," said Joseph Pidala, M.D., M.S., a medical oncologist and study principal investigator. "Existing pharmacologic strategies do not adequately prevent acute graft vs. host disease following allogeneic hematopoietic (blood) cell transplantation, and effective acute GVHD prevention is an important clinical goal necessary to ensure the long-term success of transplantation."

According to the authors, their study design mandated at least one year of sirolimus therapy in order to both limit the risk from chronic GVHD development and to promote the patients' immune tolerance based on the "reconstitution" of the patients' immune cells, called regulatory T cells, or "Tregs."

"Our hypothesis was that SIR-based immune suppression would suppress alloreactive T cells, support the recovery of the immune system's Tregs, and more effectively prevent GVHD," explained Pidala.

Results showed that on days 30 and 90 post transplantation, SIR/TAC-treated patients had "a significantly greater proportion of regulatory T cells among the CD 4 immune cells in their peripheral blood" and their regulatory Tregs were "functional."

The authors suggested that the "net benefit" observed in Treg reconstitution with SIR/TAC-treated patients was likely due to both the suppression of immune systems' non-Treg CD4 T cells by sirolimus, as well as the lower tacrolimus exposure for these patients as compared to patients on the MTX/TAC arm of the study.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
2. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
3. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
4. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
5. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
6. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
7. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Moffitt researcher publishes book on nutritional management of cancer treatment effects
10. Moffitt researchers find adolescents with cancer concerned about their future reproductive health
11. Moffitt Cancer Center researchers working at frontiers of melanoma research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, ... ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the emotional and ... convenient, clear braces in Cincinnati, OH. Patients no longer need to feel the esthetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for ... to sell luxury homes anywhere on the planet. The luxury home market is alive ... to Houston city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , ... Surprising Truth about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services ... p.m. Eastern time, will be presented by Captain Rommie Duckworth, LP, a career fire ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... pediatric dentistry options for its patients on Long Island, New York. , ... well being, and is one of the biggest trends in dentistry today. ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... ingredient solutions for the food and beverage industry offers Citri-Fi®, a natural citrus ... during the purchasing decision process. As a result, labels need to deliver simple, ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 2017  Semler Scientific, Inc. (OTCQB: SMLR), an ... improve the clinical effectiveness and efficiency of healthcare ... quarter ended March 31, 2017. ... to identify when preventive care options are appropriate, ... heart attacks or strokes occur," said Doug ...
(Date:5/6/2017)... SKANEATELES FALLS, N.Y. , May 5, 2017 /PRNewswire/ ... expansion that will add approximately 100,000 square feet to ... announced in September 2016 its commitment to bring more ... York , where Welch Allyn has maintained a ... facility will help accommodate these new positions, a large ...
(Date:5/4/2017)... Israel , May 4, 2017  DarioHealth Corp. ... mobile health and big data solutions, today announced that ... A&D Company, and STI Technologies Limited to lower diabetes ... immediately. Through STI,s innoviCares card, which is available throughout ... , DarioHealth customers will be eligible for additional savings ...
Breaking Medicine Technology: